An international phase-2 trial of a CAR-T cell therapy -to be published online Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego) -found that 52% of patients responded favorably to the therapy; 40% had a complete response and 12% had a partial response.
All news from Immuno Haematology & Blood Transfusion
UT Southwestern biochemist and Breakthrough Prize winner Dr. Zhijian "James" Chen's newest study answer a longstanding question in the field of innate immunity. Scientists have long wondered how one protein, NLRP3, can promote inflammation in response to a wide range of seemingly unrelated stimuli.
Adoptive cell transfer (ACT) is a promising cancer immunotherapy that involves isolating T cells from cancer patients that are capable of targeting their tumor, selecting the more active T cells and expanding those in the lab, and then transfusing them back into patients.
The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.
Some severe forms of leukemia develop because proteins on the epigenetic level lose their regulative function. Now, in a broad international collaboration, UK researchers have identified molecules that can effectively inhibit the dysregulated proteins. In the journal Angewandte Chemie, researchers report the discovery, design, and testing of potential drugs on the cellular level.
Researchers in Israel have discovered that breast tumors can boost their growth by recruiting stromal cells originally formed in the bone marrow. The study, which will be published November 23 in the Journal of Experimental Medicine, reveals that the recruitment of bone marrow-derived fibroblasts lowers the odds of surviving breast cancer, but suggests that targeting these cells could be an effective way of treating the disease.
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could improve AML survival rates, which have not budged in recent years.
How does individual develop cells choose and commit to their "identity" to become, for example, an immune cell, or a muscle cell, or a neuron? T-lymphocytes are cells in the immune system that act as "intelligence agents" they circulate throughout the body, detect threats, and determine what kind of response the immune system should make.